Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PROKIDNEY CORP. (PROK)

ProKidney had $141.9 million in cash at Sept. 30, 2026, funding plans into mid-2027

Neutral Impact 3 of 5 earnings

ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.

Key points

  • Cash and marketable securities were $141.9 million as of September 30, 2026.
  • The updated investor presentation says current cash is expected to support operating plans into mid-2027.
  • The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
  • The filing does not include revenue, net income or loss, or earnings per share.

The filing

CompanyPROKIDNEY CORP. (PROK)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:00 AM ET
Accession number0001193125-26-452616

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:10 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.